SalubRx Therapeutics Inc. has a pipeline of clinical and preclinical New Chemical Entities (NCEs) as clinical leads, back-ups and new developments. Characteristic profiles and properties: Biopharmaceutics Classification System (BCS) 1, low Cost of Goods, API stability up to 3 years, 90 day primate toxicology with minimal findings and safety in elderly patients.
|SBX-613||Parkinson's Dyskinesia (backup)||nNOS||Pre-Clin|
|SBX-677||Parkinson's Dyskinesia / Neurodegeneration||nNOS/iNOS||Pre-Clin|
|SBX-774||Parkinson's Dyskinesia / Neurodegeneration (backup)||nNOS/iNOS||Discovery|
CoM composition of matter patent; others possible